Share

China National Accord Medicines Corporation Ltd. Stocks

CN¥ 26.05Last Updated 13.02.2026

Issuer Rating

6/7

Performance

Favourable

Risk

Low

Recommendation

Buy

Market Cap

CN¥ 1.81B

Buy
Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
CN¥ 26.05
Key Takeaways

Risk factor

Negligible price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

China National Accord Medicines Corporation Ltd. engages in the distribution of medicine and pharmaceutical products. The company sells Chinese traditional, bio-chemical, biological, and diagnosis medicines, as well as antibiotics; chemical preparations; food products; chemical products; and various commodities. It also engages in the sale of medical apparatus and instruments; provision of freight transportation, storage, loading...

Company Valuation

Greatly undervalued
7/7

Considering past and projected metrics, the stock is distinctly 'cheaper' than its peers. In particular, the stock is underpriced on P/E, 'cheap' on EV/EBITDA, undervalue

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Neutral
4/7

The average target price of 000028.SZ is 27 and suggests 4% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendatio

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks